Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

First‐in‐Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID‐19
Peter Chen, Gourab Datta, Ying Grace Li, et al.
Clinical Pharmacology & Therapeutics (2021) Vol. 110, Iss. 6, pp. 1467-1477
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Antibody-mediated neutralization of SARS-CoV-2
Henning Gruell, Kanika Vanshylla, Timm Weber, et al.
Immunity (2022) Vol. 55, Iss. 6, pp. 925-944
Open Access | Times Cited: 120
Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19
Michael Dougan, Masoud Azizad, Peter Chen, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 69
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
Kara W. Chew, Carlee Moser, Eric S. Daar, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 43
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19
Caroline Hirsch, Yun Soo Park, Vanessa Piechotta, et al.
Cochrane library (2022) Vol. 2022, Iss. 6
Open Access | Times Cited: 40
The anti–SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination
Robert J. Benschop, Jay Tuttle, Lin Zhang, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 655
Open Access | Times Cited: 29
Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis
Jiawen Deng, Kiyan Heybati, Harikrishnaa Ba Ramaraju, et al.
Infection (2022) Vol. 51, Iss. 1, pp. 21-35
Open Access | Times Cited: 26
Evolution of a globally unique SARS-CoV-2 Spike E484T monoclonal antibody escape mutation in a persistently infected, immunocompromised individual
Peter Halfmann, Nicholas R. Minor, Luis A. Haddock, et al.
Virus Evolution (2022) Vol. 9, Iss. 2
Open Access | Times Cited: 24
Immunobiology and immunotherapy of COVID-19
Kenneth Lundström
Progress in molecular biology and translational science (2025)
Closed Access
Clinical efficacy and safety of SARS-CoV-2-neutralizing monoclonal antibody in patients with COVID-19: A living systematic review and meta-analysis
Su‐Yeon Yu, Miyoung Choi, Chelim Cheong, et al.
Journal of Microbiology Immunology and Infection (2023) Vol. 56, Iss. 5, pp. 909-920
Open Access | Times Cited: 8
An Update on SARS-CoV-2 Clinical Trial Results—What We Can Learn for the Next Pandemic
Edi Dharmana, Juliane Brun, Michelle L. Hill, et al.
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 354-354
Open Access | Times Cited: 8
Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together
Lin Zhang, Josh Poorbaugh, Michael Dougan, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 19
A Quantitative Modeling and Simulation Framework to Support Candidate and Dose Selection of Anti‐SARS‐CoV‐2 Monoclonal Antibodies to Advance Bamlanivimab Into a First‐in‐Human Clinical Trial
Emmanuel Chigutsa, Eric Jordie, Matthew M. Riggs, et al.
Clinical Pharmacology & Therapeutics (2021) Vol. 111, Iss. 3, pp. 595-604
Open Access | Times Cited: 18
Identification of antibody-resistant SARS-CoV-2 mutants via N4-Hydroxycytidine mutagenesis
Priya Kumar, Xiaoxiao Zhang, Rahul Shaha, et al.
Antiviral Research (2024) Vol. 231, pp. 106006-106006
Open Access | Times Cited: 2
Rapid isolation of anti-idiotype aptamers for quantification of human monoclonal antibodies against SARS-CoV-2 spike protein
Kechun Wen, Wenting Dai, Xin Meng, et al.
Biosensors and Bioelectronics (2023) Vol. 246, pp. 115842-115842
Open Access | Times Cited: 6
Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19
Kara W. Chew, Carlee Moser, Eric S. Daar, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 14
Level and Duration of IgG and Neutralizing Antibodies to SARS-CoV-2 in Children with Symptomatic or Asymptomatic SARS-CoV-2 Infection
Alka Khaitan, Dibyadyuti Datta, Caitlin Bond, et al.
ImmunoHorizons (2022) Vol. 6, Iss. 6, pp. 408-415
Open Access | Times Cited: 9
Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults
Peter Schmidt, Jean Gong, Kristin Narayan, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 5, pp. 1365-1377
Open Access | Times Cited: 5
Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab
Jonathan T. Sims, Josh Poorbaugh, Ching-Yun Chang, et al.
Journal of Translational Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 8
Utilizing targeted integration CHO pools to potentially accelerate the GMP manufacturing of monoclonal and bispecific antibodies
Gavin C. Barnard, Michelle Zhou, Amy Shen, et al.
Biotechnology Progress (2023) Vol. 40, Iss. 1
Closed Access | Times Cited: 4
Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and meta-analysis
Behnam Amani, Lida Khodavirdilou, Kourosh Rajabkhah, et al.
World Journal of Virology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 1
Characterisation of the antibody-mediated selective pressure driving intra-host evolution of SARS-CoV-2 in prolonged infection
Michael Schoefbaenker, Theresa Günther, Eva U. Lorentzen, et al.
PLoS Pathogens (2024) Vol. 20, Iss. 10, pp. e1012624-e1012624
Open Access | Times Cited: 1
Cardiovascular Adverse Events Associated with Monoclonal Antibody Products in Patients with COVID-19
Jingrui Zou, Fuyuan Jing
Pharmaceuticals (2022) Vol. 15, Iss. 12, pp. 1472-1472
Open Access | Times Cited: 5
Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS‐CoV‐2 neutralizing monoclonal antibody ABBV‐47D11 in patients with COVID‐19
Mohamad Shebley, Stanley Wang, Izna Ali, et al.
Pharmacology Research & Perspectives (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 5
Quality of reporting of adverse events in clinical trials of covid-19 drugs: systematic review
Karima Madi, Clara Flumian, Pascale Olivier, et al.
BMJ Medicine (2023) Vol. 2, Iss. 1, pp. e000352-e000352
Open Access | Times Cited: 2
Long-term cellular immune response in immunocompromised unvaccinated COVID-19 patients undergoing monoclonal antibody treatment
Laura Thümmler, Margarethe Konik, Monika Lindemann, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top